Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Capsaicin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 known ✓ | Q8NER1 | 9/20 | 0.83 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.83 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.83 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.83 |
| ▸ | MAPT | P10636 | 3/20 | 0.83 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.83 |
| ▸ | MEN1 | O00255 | 2/20 | 0.83 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.83 |
| ▸ | TP53 | P04637 | 2/20 | 0.83 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.83 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.83 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.83 |
| ▸ | KDM1A | O60341 | 1/20 | 0.83 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.83 |
| ▸ | LMNA | P02545 | 1/20 | 0.83 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.83 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.83 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.83 |
| ▸ | HTR2C | P28335 | 1/20 | 0.83 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Capsaicin SCHEMBL3397147 | 1.00 | TRPV1 (0.83) | TRPV1CYP1A2CYP3A4ALDH1A1MAPT | |
| Capsaicin SCHEMBL1155587 | 1.00 | TRPV1 (0.83) | TRPV1CYP1A2CYP3A4ALDH1A1MAPT | |
| Capsaicin SCHEMBL1155584 | 1.00 | TRPV1 (0.83) | TRPV1CYP1A2CYP3A4ALDH1A1MAPT | |
| Zucapsaicin SCHEMBL289300 | 0.96 | TRPV1 (0.90) | TRPV1CYP1A2CYP3A4ALDH1A1MAPT | |
| Capsaicin SCHEMBL28114637 | 0.96 | TRPV1 (0.90) | TRPV1CYP1A2CYP3A4ALDH1A1MAPT | |
| Capsaicin SCHEMBL1757933 | 0.94 | TRPV1 (0.86) | TRPV1CYP1A2CYP3A4ALDH1A1MAPT | |
| Capsaicin SCHEMBL1757936 | 0.94 | TRPV1 (0.86) | TRPV1CYP1A2CYP3A4ALDH1A1MAPT | |
| SCHEMBL16309566 | 0.92 | TRPV1 (0.98) | TRPV1CYP1A2CYP3A4ALDH1A1MAPT | |
| SCHEMBL31182202 | 0.92 | TRPV1 (0.98) | TRPV1CYP1A2CYP3A4ALDH1A1MAPT | |
| SCHEMBL1878911 | 0.92 | TRPV1 (0.98) | TRPV1CYP1A2CYP3A4ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8987328-B2 | Esters of capsaicinoids as dietary supplements | TRINITY LABORATORIES, INC. (US) | 2015-03-24 | — | — | US | claimed |
| US-20100120912-A1 | Esters of capsaicinoids as dietary supplements | TRINITY LABORATORIES INC. (US) | 2010-05-13 | — | — | US | claimed |
| US-8987328-B2 | Esters of capsaicinoids as dietary supplements | TRINITY LABORATORIES, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20100120912-A1 | Esters of capsaicinoids as dietary supplements | TRINITY LABORATORIES INC. (US) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120912-A1 | Esters of capsaicinoids as dietary supplements | SI, LIPA, PNLIP | TRPV1 12/4885CYP1A2 215/4885CYP3A4 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.